Capital Group Investment Management Pte. Ltd. Bei Gene, Ltd. Transaction History
Capital Group Investment Management Pte. Ltd.
- $444 Million
- Q2 2024
A detailed history of Capital Group Investment Management Pte. Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital Group Investment Management Pte. Ltd. holds 16,030 shares of BGNE stock, worth $3.27 Million. This represents 0.51% of its overall portfolio holdings.
Number of Shares
16,030
Previous 16,030
-0.0%
Holding current value
$3.27 Million
Previous $2.51 Million
8.74%
% of portfolio
0.51%
Previous 0.47%
Shares
5 transactions
Others Institutions Holding BGNE
# of Institutions
217Shares Held
42.1MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.16 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.43 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.06 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$1.02 Billion0.52% of portfolio
-
Baillie Gifford & CO3.68MShares$752 Million0.42% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $21.2B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...